Evidence map›Paper›PMID 32253717›Full record

ArticleClinical drug investigation2020

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage: A Safety and Tolerability Study.

Jesse J Corry, Ganesh Asaithambi, Arif M Shaik, Jeffrey P Lassig, Emily H Marino, Bridget M Ho, Amy L Castle, Nilanjana Banerji, Megan E Tipps

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Clinical drug investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03000283 (Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03000283 phase1completednot on this map

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

TypeinterventionalSponsorJesse CorryRan2017 to 2019Enrolled7ConditionsCerebral Hemorrhage, Cerebral Edema, Intracerebral Hemorrhage, StrokeArmsConivaptan
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. New targets in spontaneous intracerebral hemorrhage.Current opinion in neurology · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Emerging therapeutic targets for cerebral edema.Expert opinion on therapeutic targets · 2021
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jesse J CorryJohn Nasseff Neuroscience Specialty Clinic, United Hospital Part of Allina Health, 310 Smith Ave N, MR 64440, Ritchie Building, Suite 440, Saint Paul, MN, 55102, USA. Jesse.Corry@allina.com.
Ganesh AsaithambiJohn Nasseff Neuroscience Specialty Clinic, United Hospital Part of Allina Health, 310 Smith Ave N, MR 64440, Ritchie Building, Suite 440, Saint Paul, MN, 55102, USA.
Arif M ShaikJohn Nasseff Neuroscience Specialty Clinic, United Hospital Part of Allina Health, 310 Smith Ave N, MR 64440, Ritchie Building, Suite 440, Saint Paul, MN, 55102, USA.
Jeffrey P LassigMidwest Radiology, United Hospital Part of Allina Health, Saint Paul, MN, USA.
Emily H MarinoNeuroscience Research, United Hospital Part of Allina Health, Saint Paul, MN, USA.
Bridget M HoNeuroscience Research, United Hospital Part of Allina Health, Saint Paul, MN, USA.
Amy L CastleJohn Nasseff Neuroscience Specialty Clinic, United Hospital Part of Allina Health, 310 Smith Ave N, MR 64440, Ritchie Building, Suite 440, Saint Paul, MN, 55102, USA.
Nilanjana BanerjiNeuroscience Research, United Hospital Part of Allina Health, Saint Paul, MN, USA.
Megan E TippsNeuroscience Research, United Hospital Part of Allina Health, Saint Paul, MN, USA.
Abbott Northwestern Hospital · USUnited Hospital · USAllina Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPerihematomal edema (PHE) growth in intracranial hemorrhage (ICH) is a biomarker for worse outcomes. Although the management of PHE is potentially beneficial for ICH patients, there is currently no proven clinical therapy that both reduces PHE and improves outcomes in this population.

objectiveTo examine the safety and tolerability of conivaptan, a non-peptide vasopressin (AVP) receptor antagonist, for the management of PHE in ICH patients.

methodsWe performed a single-center, open-label, phase I study in seven patients with ICH at risk for developing PHE. Conivaptan (20 mg) was administered every 12 h for 2 days, along with the standard ICH management. Electrolyte levels, renal and cardiac function, and vital signs were monitored throughout treatment. Neurological status, ICH, and PHE volumes were assessed at study baseline, 24 h, 72 h, and 7 days from the first conivaptan administration, as well as at the 3-month follow-up.

resultsConivaptan was well tolerated in our patients. We observed the expected increase in sodium levels following conivaptan administration (p = 0.01), with no change in cardiac or renal function. All patients survived to follow-up, and adverse event rates were comparable with those of the neurocritical care unit overall.

conclusionsThese data indicate that conivaptan can be safely administered to ICH patients and support further clinical investigation into the efficacy of this drug for ICH treatment. CLINICAL

trial registrationclinicaltrials.gov; NCT03000283, 22 December 2016.

Indexed as

AgedBenzazepinesBrain EdemaCerebral HemorrhageFemaleHumansMaleMiddle AgedBenzazepinesconivaptan

Identifiers

PMID32253717
OpenAlexW3014483806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.